Verve Therapeutics announces the price of its initial public offering

0


CAMBRIDGE, Mass .– (COMMERCIAL THREAD) – Verve Therapeutics, a biotechnology company pioneering a new approach to treating cardiovascular disease with single-treatment gene-editing drugs, today announced the price of its initial public offering of 14,035,789 common shares at the public price of $ 19.00 per share. The gross proceeds of the offering for Verve, before the deduction of underwriting discounts and commissions and offering fees, are expected to be $ 266.7 million. All shares are offered by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to 2,105,368 additional shares of its common shares at the initial public offering price less any rebates and subscription fees.

The shares are expected to begin trading on the Nasdaq Global Select Market on June 17, 2021, under the ticker symbol “VERV”. The offer is scheduled to close on June 21, 2021, subject to the satisfaction of the usual closing conditions.

JP Morgan, Jefferies, Guggenheim Securities and William Blair are acting as book co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on June 16, 2021. The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, can be obtained from JP Morgan Securities LLC, c / o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email to prospectus-eq_fi@jpmchase.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10012, by phone at 877-821-7388 or by email at prospectus_department@Jefferies.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by phone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or William Blair & Company, LLC, Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by phone at (800) 621-0687, or by email at prospectus@williamblair.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or other jurisdiction in which such an offer, solicitation or sale would be illegal. before registration. or qualification under the securities laws of any such state or jurisdiction.

About Verve Therapeutics

Verve Therapeutics is a genetic drug company pioneering a new approach to the management of cardiovascular disease, transforming the treatment of chronic management into single-treatment gene-editing drugs. The company’s two initial programs target PCSK9 and ANGPTL3, genes that have been widely validated as targets for lowering blood lipids such as low density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s flagship product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver to disrupt the production of PCSK9 proteins in the blood and thereby reduce blood LDL-C levels, with the goal of reducing the risk of cardiovascular disease in the patient. VERVE-101, currently in studies enabling IND, is initially being developed for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com.



Source link

Leave A Reply

Your email address will not be published.